{"nctId":"NCT00529152","briefTitle":"Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients","startDateStruct":{"date":"2007-08"},"conditions":["Iron Overload"],"count":100,"armGroups":[{"label":"A","type":"OTHER","interventionNames":["Drug: Deferiprone"]}],"interventions":[{"name":"Deferiprone","otherNames":["Ferriprox Oral Solution"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who are ≤ 10 years of age.\n* Patients who have a confirmed diagnosis of transfusion-dependent anemia, other than Blackfan-Diamond anemia, and have chronic iron overload requiring chelation therapy.\n* Patients who are in a chronic transfusion program, and who have received at least eight (8) red blood cell transfusions per year for a minimum of one year.\n* Patients who are iron overloaded as assessed by serum ferritin concentration greater than 1000 µg/L.\n\nExclusion Criteria:\n\n* Patients who have a diagnosis of Blackfan-Diamond anemia.\n* Patients who have experienced neutropenia/agranulocytosis (absolute neutrophil count (ANC) \\< 1.5 x 109/L) or thrombocytopenia (platelet count \\< 50.0 x 109/L).\n* Patients who have had previous treatment with Ferriprox and presented serious adverse reaction or intolerance requiring withdrawal of Ferriprox.\n* Patients with evidence of abnormal liver function (ALT level \\> 3 times the upper limit of normal; entry may be delayed until values return to normal).\n* Patients with evidence of renal failure, characterized by serum creatinine level \\> 2 times the upper limit of normal; entry may be delayed until values return to normal.","healthyVolunteers":false,"sex":"ALL","maximumAge":"10 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Occurrence of Adverse Events","description":"Number of Adverse Events over 24 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Serum Ferritin Concentration From Baseline.","description":"The change in serum ferritin concentration from baseline to week 24 was measured and analyzed for all participants in the study","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-355.5","spread":"978.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}}